<DOC>
	<DOC>NCT00920855</DOC>
	<brief_summary>The primary objective of this study is to assess the safety and tolerability of bendamustine as combination therapy with bortezomib for patients with relapsed/refractory multiple myeloma (MM).</brief_summary>
	<brief_title>Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>The patient: has a diagnosis of multiple myeloma. currently has multiple myeloma with measurable disease. must have received at least 1 previous treatment regimen and shows signs of progressive disease at the time of study entry. if a woman of child bearing potential (not surgically sterile or at least 12 months naturally postmenopausal), must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study. if a man, must agree to use an acceptable method of contraception throughout the study and for 90 days after last dose study drug. must have an Eastern Cooperative Oncology Group (ECOG) performance status not greater than 2. must have a lifeexpectancy of greater than 3 months. must meet specific protocolrelated hematological and laboratory criteria within 14 days of enrollment. The patient has: had a prior malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix). plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (Mprotein) and skin changes (POEMS) syndrome. plasma cell leukemia. nonmeasurable multiple myeloma. Common Terminology Criteria for Adverse Events (CTCAE) grade 2 (or greater) peripheral neuropathy within 14 days before enrollment. previously participated in a Cephalonsponsored clinical study with bendamustine. impaired cardiac function or clinically significant cardiac diseases. undergone major surgery within 4 weeks prior to screening or has not recovered from side effects of such therapy. severe hypercalcemia. other concurrent severe and/or uncontrolled medical or psychiatric conditions. known positivity for human immunodeficiency virus (HIV) or hepatitis B or C. a history of allergic reaction attributable to compounds of similar chemical or biological composition to bendamustine, bortezomib, boron, or mannitol. received chemotherapy within 3 weeks before enrollment, with the exception of nitrosoureas, which should be discontinued at least 6 weeks before enrollment. received corticosteroids (greater than 10 mg/day prednisone or equivalent) within 3 weeks before enrollment. received immunotherapy, antibody, or radiation therapy within 4 weeks before enrollment. a status as a pregnant or lactating woman. Any women becoming pregnant during the study will be withdrawn from the study. a status as a male whose sexual partner is a woman of childbearing potential not using effective birth control. used an investigational drug within 1 month before the screening visit.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>